Collegium Pharmaceutical, Inc. – Product Pipeline Review – H2 2011

Date: November 1, 2011
Pages: 48
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C3DD8B81D56EN
Leaflet:

Download PDF Leaflet

Collegium Pharmaceutical, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Collegium Pharmaceutical, Inc. - Product Pipeline Review - H2 2011” provides data on the Collegium Pharmaceutical, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Collegium Pharmaceutical, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Collegium Pharmaceutical, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Collegium Pharmaceutical, Inc. - Brief Collegium Pharmaceutical, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Collegium Pharmaceutical, Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Collegium Pharmaceutical, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Collegium Pharmaceutical, Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Collegium Pharmaceutical, Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Collegium Pharmaceutical, Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Collegium Pharmaceutical, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Collegium Pharmaceutical, Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Collegium Pharmaceutical, Inc. and identify potential opportunities in those areas.
Collegium Pharmaceutical, Inc. Snapshot
Collegium Pharmaceutical, Inc. Overview
Key Information
Key Facts
Collegium Pharmaceutical, Inc. – Research and Development Overview
Key Therapeutic Areas
Collegium Pharmaceutical, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Collegium Pharmaceutical, Inc. – Pipeline Products Glance
Collegium Pharmaceutical, Inc. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Collegium Pharmaceutical, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Collegium Pharmaceutical, Inc. – Drug Profiles
COL-003
  Product Description
  Mechanism of Action
  R&D Progress
COL-112
  Product Description
  Mechanism of Action
  R&D Progress
COL-117
  Product Description
  Mechanism of Action
  R&D Progress
COL-118
  Product Description
  Mechanism of Action
  R&D Progress
COL-131
  Product Description
  Mechanism of Action
  R&D Progress
COL-171
  Product Description
  Mechanism of Action
  R&D Progress
Collegium Pharmaceutical, Inc. – Pipeline Analysis
Collegium Pharmaceutical, Inc. – Pipeline Products by Therapeutic Class
Collegium Pharmaceutical, Inc. - Pipeline Products By Target
Collegium Pharmaceutical, Inc. – Pipeline Products by Route of Administration
Collegium Pharmaceutical, Inc. – Pipeline Products by Molecule Type
Collegium Pharmaceutical, Inc. – Recent Pipeline Updates
Collegium Pharmaceutical, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Oct 31, 2007: Collegium Pharmaceutical Inc. Announces Final Study Results Of Its Successfully Completed Proof Of Concept Study For Its Abuse Deterrent Sustained Release Opioid Product
Oct 31, 2007: Collegium Pharmaceutical Inc. Announces Successful Completion Of Proof Of Concept Study For Its Abuse Deterrent Sustained Release Opioid Product
Mar 31, 2010: Collegium Pharmaceutical Receives Notice Of Allowance For US Patent Covering Novel Once-A-Day Formulation Of Milnacipran
Mar 29, 2010: Collegium Files Investigational New Drug Application For COL-172
Sep 26, 2011: Collegium Pharmaceutical Announces Successful Type A Meeting With FDA For Tamper-Resistant, Extended Release Opioid
May 26, 2009: Collegium Pharmaceutical Inc. Announces Notice Of Allowance For U.S. Patent Covering Its Novel Combination Allergic Rhinitis Product
Dec 17, 2007: Collegium Pharmaceutical To Advance Its Allergic Rhinitis Product Into Phase III Trials
Jun 15, 2007: Collegium Pharmaceutical Inc., Announces The Filing Of IND For Abuse Deterrent Sustained Release Opioid Product
Jul 12, 2007: Collegium Pharmaceutical Inc. Announces FDA Acceptance of IND for its Abuse Deterrent Sustained Release Opioid Product
Jun 10, 2010: Collegium Receives FDA Fast Track Designation For COL-172
Jun 10, 2009: Collegium Pharmaceutical Inc. Announces Submission Of A Request For Special Protocol Assessment To FDA For Pivotal Trial For Tamper Resistant, Extended Release Opioid (COL-003)
Financial Deals Landscape
Collegium Pharmaceutical, Inc., Deals Summary
Collegium Pharmaceutical, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Collegium Pharmaceutical Secures $20 Million In Series D Financing
Partnerships
BTG International Partners With Collegium Pharmaceutical
Collegium Pharmaceutical Enters Into Co-Development Agreement With Mutual Pharmaceutical
BTG International Signs Agreement With Collegium Pharmaceutical
Licensing Agreements
Accentia Biopharmaceuticals Enters Into Licensing Agreement With Collegium Pharmaceuticals
Healthpoint Enters Into Licensing Agreement With Collegium Pharmaceutical
Cypress Bioscience Enters Into Licensing Agreement With Collegium Pharmaceutical
Debt Offering
Collegium Pharmaceutical Raises $1 Million In Debt Financing
Asset Transactions
Lupin Acquires Rights To AllerNaze From Collegium Pharmaceutical
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Collegium Pharmaceutical, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Collegium Pharmaceutical, Inc. – Pipeline by Stage of Development, H2 2011
Collegium Pharmaceutical, Inc. – Filed, H2 2011
Collegium Pharmaceutical, Inc. – Phase III, H2 2011
Collegium Pharmaceutical, Inc. - Pipeline By Therapeutic Class, H2 2011
Collegium Pharmaceutical, Inc. - Pipeline By Target, H2 2011
Collegium Pharmaceutical, Inc. – Pipeline By Route of Administration, H2 2011
Collegium Pharmaceutical, Inc. – Pipeline By Molecule Type, H2 2011
Collegium Pharmaceutical, Inc. – Recent Pipeline Updates, H2 2011
Collegium Pharmaceutical, Inc., Deals Summary
Collegium Pharmaceutical Secures $20 Million In Series D Financing
BTG International Partners With Collegium Pharmaceutical
Collegium Pharmaceutical Enters Into Co-Development Agreement With Mutual Pharmaceutical
BTG International Signs Agreement With Collegium Pharmaceutical
Accentia Biopharmaceuticals Enters Into Licensing Agreement With Collegium Pharmaceuticals
Healthpoint Enters Into Licensing Agreement With Collegium Pharmaceutical
Cypress Bioscience Enters Into Licensing Agreement With Collegium Pharmaceutical
Collegium Pharmaceutical Raises $1 Million In Debt Financing
Lupin Acquires Rights To AllerNaze From Collegium Pharmaceutical

LIST OF FIGURES

Collegium Pharmaceutical, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Collegium Pharmaceutical, Inc. – Pipeline by Stage of Development, H2 2011
Collegium Pharmaceutical, Inc. – Pipeline By Therapeutic Class, H2 2011
Collegium Pharmaceutical, Inc. - Pipeline By Target, H2 2011
Collegium Pharmaceutical, Inc. – Pipeline By Route of Administration, H2 2011
Collegium Pharmaceutical, Inc. – Pipeline By Molecule Type, H2 2011

Ask Your Question

Collegium Pharmaceutical, Inc. – Product Pipeline Review – H2 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: